An AI biology company
AI
| Round | Amount | Announced | Lead | Verified | Status | Sources |
|---|---|---|---|---|---|---|
| Seed ext. seed-extension financing | $14.9M €13 million | 2026-09-22 | Sofinnova Partners | 1 | [ CHECK ] | 1 |
[ VERIFIED ]0.61 read against its primary page [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search: "pre-seed round" led by announces·[ SCRAPE ]1 page read: european-biotechnology.com·[ JSON ]round extracted with a schema, grounded to one sentence·[ VERIFY ]confirmedread back against its page by Firecrawl·[ AGENT ]dossier built by the Firecrawl agent | ||||||
Ingenix builds a biological reasoning engine that helps pharmaceutical and biotech teams make translational and clinical R&D decisions and reduce uncertainty in drug development.
| Round | Amount | Announced | Lead |
|---|---|---|---|
| Seed | €9 million | 2025-04 | Inovo VC |
| seed-extension | €13m | 2026-06-03 | Sofinnova Partners |
Ingenix is addressing a drug-development bottleneck by connecting biological data across modalities and scales and producing reasoning traces that scientists can interrogate, while a recent oncology engagement reportedly produced actionable ADC candidates in minutes rather than the years and millions of euros of research previously required. The company has raised a €9 million seed round and a €13m seed extension to scale its Biological Reasoning Engine and expand access to pharma and biotech partners, but IFC described it as pre-revenue in July 2025.
